<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0">
  <channel>
    <title>DSpace Community:</title>
    <link>https://ir.ymlib.yonsei.ac.kr/handle/22282913/169013</link>
    <description />
    <pubDate>Mon, 20 Apr 2026 14:04:20 GMT</pubDate>
    <dc:date>2026-04-20T14:04:20Z</dc:date>
    <item>
      <title>Transglutaminase 2 exacerbates ovarian cancer survival by directly inactivating GSK3β</title>
      <link>https://ir.ymlib.yonsei.ac.kr/handle/22282913/211213</link>
      <description>Title: Transglutaminase 2 exacerbates ovarian cancer survival by directly inactivating GSK3β
Authors: Lee, Ho; Kang, Joon Hee; Kim, Hyun Jung; Heo, Kyun; Park, Mi Kyung; Park, Jeong Hwan; Lee, Byung Il; Yook, Jong In; Kim, Soo-Youl
Abstract: Elevated expression of transglutaminase 2 (TGase 2, EC 2.3.2.13, protein-glutamine gamma-glutamyltransferase, gene name TGM2) is known as one of the most upregulated genes during epithelial-mesenchymal transition (EMT) in ovarian cancer. Despite initial complete responses to conventional chemotherapy, ovarian cancer often recurs with metastasis, presenting a significant clinical challenge. Drug-resistant ovarian cancer cells exhibit markedly higher levels of TGase 2 compared to normal ovarian epithelium, which is associated with EMT activation, enabling them to evade chemotherapy effects. Intracellular TGase 2 is recognized as a key factor in maintaining the mesenchymal phenotype. Therefore, while EMT expression can be effectively reversed by inhibiting TGase 2, the underlying mechanism of this effect remains unclear. We found that TGase 2 promotes EMT by directly binding to glycogen synthase kinase-3 beta (GSK3 beta), promoting the stabilization of beta-catenin. Domain mapping revealed that the N-terminus of TGase 2 interacts with the mid-region of GSK3 beta, leading to the autophagic degradation of GSK3 beta. Pharmacological disruption of this N-terminal interaction by streptonigrin, in combination with standard chemotherapy, extended overall survival in a xenograft model of ovarian cancer. This study identified TGase 2 as a pivotal regulator of EMT-driven metastasis and drug resistance.</description>
      <pubDate>Sun, 01 Feb 2026 00:00:00 GMT</pubDate>
      <guid isPermaLink="false">https://ir.ymlib.yonsei.ac.kr/handle/22282913/211213</guid>
      <dc:date>2026-02-01T00:00:00Z</dc:date>
    </item>
    <item>
      <title>Dental drugs with proarrhythmic risk in patients with Brugada syndrome: precaution instructions for practices in the field of orofacial pain</title>
      <link>https://ir.ymlib.yonsei.ac.kr/handle/22282913/211221</link>
      <description>Title: Dental drugs with proarrhythmic risk in patients with Brugada syndrome: precaution instructions for practices in the field of orofacial pain
Authors: Han, Dawool; Cho, Na Yeong; Cho, Eunae Sandra; Roh, Seung-Young
Abstract: Orofacial pain, diagnosed and treated in a subfield of dentistry, highly relies on long-term psychotropic, neuromodulating, and analgesic regimens that have the potential to alter cardiac ion channels and autonomic tone. In patients with inherited arrhythmia syndromes such as Brugada syndrome (BrS), these drugs may unmask a type 1 Brugada electrocardiographic pattern or trigger malignant ventricular arrhythmias and sudden cardiac death, yet most dental guidance addresses only short-term use of local anesthetics. In this narrative review, we synthesize evidence on the arrhythmogenic potential of medications used for orofacial pain-non-steroidal anti-inflammatory drugs, tricyclic antidepressants, anticonvulsants, and primary headache therapies. Finally, we propose a pragmatic risk-stratified approach for orofacial pain specialists. Incorporating channelopathy-specific precautions into orofacial pain pharmacotherapy may reduce drug-induced ventricular arrhythmias and sudden cardiac death while preserving effective long-term pain control.</description>
      <pubDate>Sun, 01 Feb 2026 00:00:00 GMT</pubDate>
      <guid isPermaLink="false">https://ir.ymlib.yonsei.ac.kr/handle/22282913/211221</guid>
      <dc:date>2026-02-01T00:00:00Z</dc:date>
    </item>
    <item>
      <title>Taste Dysfunction in Oral Candidiasis: Impact of Candida Carriage and Hyphal Presence</title>
      <link>https://ir.ymlib.yonsei.ac.kr/handle/22282913/211551</link>
      <description>Title: Taste Dysfunction in Oral Candidiasis: Impact of Candida Carriage and Hyphal Presence
Authors: Park, Younjung; Jung, Hyo-Jung; Hwang, Sin Hye; Cho, Eunae Sandra; Ahn, Hyung-Joon
Abstract: Background Taste dysfunction is a common symptom of oral candidiasis; however, its underlying mechanisms remain unclear.Objectives This study aimed to determine whether Candida albicans carriage, particularly its hyphal phenotype, is associated with impaired taste sensitivity.Patients/Methods Fifty-seven participants were divided into three groups: noncarriers (n = 20), carriers without hyphae (n = 20), and carriers with hyphae (n = 17). Tongue biofilm samples were collected for Candida culture and smear tests. Salivary flow rates were measured, and taste sensitivity was assessed using standardised taste strips. Carriers underwent topical fluconazole treatment, and post-treatment taste sensitivity was re-evaluated.Results Carriers exhibited reduced sensitivity to sweet and bitter tastes, with an additional decline in umami sensitivity among those with hyphae. In addition, both unstimulated and stimulated salivary flow rates were significantly lower in Candida carriers than in noncarriers. Topical fluconazole treatment resulted in a marked reduction in hyphae and significant improvement in taste sensitivity.Conclusions This study revealed differences in salivary flow and taste sensitivity between noncarriers and Candida albicans carriers. The presence of hyphal forms was strongly associated with greater impairment in taste function. Improvement following antifungal therapy suggests that hyphal invasion may play a key role in the pathogenesis of taste dysfunction in oral candidiasis.</description>
      <pubDate>Sun, 01 Feb 2026 00:00:00 GMT</pubDate>
      <guid isPermaLink="false">https://ir.ymlib.yonsei.ac.kr/handle/22282913/211551</guid>
      <dc:date>2026-02-01T00:00:00Z</dc:date>
    </item>
    <item>
      <title>Two typical and one atypical presentation of TUGSE: Case series and literature review</title>
      <link>https://ir.ymlib.yonsei.ac.kr/handle/22282913/209738</link>
      <description>Title: Two typical and one atypical presentation of TUGSE: Case series and literature review
Authors: Gong, Mikyung; Kim, Min-Ji; Han, Seung-Yong; Kim, Hyun Sil; Nam, Woong
Abstract: Background: Traumatic ulcerative granuloma with stromal eosinophilia (TUGSE) is a rare, reactive oral mucosal lesion characterized by dense eosinophilic infiltration. Although often linked to trauma, immune-mediated mechanisms may also contribute. Clinically, TUGSE can mimic malignancy or infection. Case Presentation: We report three cases of TUGSE with variable presentations. The first two cases involved classic ulcerative lesions on the lateral tongue, both of which healed spontaneously following biopsy. The third case presented as a deep cold abscess extending from the lingual cortex to the mandibular base following third molar extraction-an uncommon presentation. All lesions were histopathologically diagnosed as TUGSE. Conclusion: These cases demonstrate the clinical spectrum of TUGSE and highlight the importance of early biopsy and histopathological evaluation in persistent oral ulcers to ensure diagnostic accuracy and guide appropriate management. Recognizing atypical presentations may help avoid misdiagnosis and unnecessary interventions.</description>
      <pubDate>Mon, 01 Dec 2025 00:00:00 GMT</pubDate>
      <guid isPermaLink="false">https://ir.ymlib.yonsei.ac.kr/handle/22282913/209738</guid>
      <dc:date>2025-12-01T00:00:00Z</dc:date>
    </item>
  </channel>
</rss>

